



## LISTING OF CLAIMS

1. (Currently amended) An oral contraceptive composition for administration to the male comprising a compound of the formula





or




wherein X is P or S;

R is C<sub>4</sub>-C<sub>24</sub> alkyl, C<sub>4</sub>-C<sub>24</sub> alkenyl, C<sub>4</sub>-C<sub>24</sub> alkoxy,



R<sub>1</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, a pharmaceutically acceptable cation or



R<sub>5</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl or a pharmaceutically acceptable cation,

R<sub>2</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl or C<sub>4</sub>-C<sub>24</sub> alkoxy, n is 0 to 4;

R<sub>3</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl, m is 3 to 10;

R<sub>4</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or COOR<sub>6</sub>;


R<sub>6</sub> is H or C<sub>1</sub>-C<sub>13</sub> alkyl; and

Y=O or NH and a pharmaceutically acceptable carrier suitable for oral delivery.


2. (Previously presented) The composition of claim 1 wherein the composition is formulated as tablet or capsule.

3. (Previously presented) The composition of claim 1 wherein the composition is formulated as a gelcap or suspension.

4. (Previously presented) The composition of claim 1 wherein the compound has the general formula



wherein R is C<sub>4</sub>-C<sub>24</sub> alkyl, C<sub>4</sub>-C<sub>24</sub> alkoxy, or




and Y is O.

5. (Previously presented) The composition of claim 4 wherein


R is C<sub>10</sub>-C<sub>18</sub> alkyl;

R<sub>1</sub> is a pharmaceutically acceptable cation or



and L is 20.


6. (Previously presented) The composition of claim 4 wherein R is



R<sub>3</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl; and

R<sub>1</sub> is a pharmaceutically acceptable cation.

7. (Previously presented) The composition of claim 1 wherein the compound has the general formula



wherein R is C<sub>4</sub>-C<sub>24</sub> alkyl or C<sub>4</sub>-C<sub>24</sub> alkoxy; and

R<sub>1</sub> and R<sub>5</sub> are independently H or a pharmaceutically acceptable cation.


8. (Previously presented) The composition of claim 7 wherein

R is C<sub>4</sub>-C<sub>24</sub> alkoxy;

R<sub>1</sub> is H or a pharmaceutically acceptable cation; and

R<sub>5</sub> is H.


9. (Previously presented) The contraceptive composition of claim 1 wherein the compound has the general formula:




wherein X is P or S;

M is a cation; and

R is C<sub>4</sub>-C<sub>24</sub> alkyl, C<sub>4</sub>-C<sub>24</sub> alkenyl, C<sub>4</sub>-C<sub>24</sub> alkoxy,



or



wherein n = 2, 3 or 4;

R<sub>2</sub> = C<sub>9</sub>-C<sub>13</sub> alkyl; and

R<sub>3</sub> = C<sub>4</sub>-C<sub>24</sub> alkyl,


10. (Previously presented) The composition of claim 9 wherein X is S.

11. (Previously presented) The composition of claim 9 wherein the composition is formulated as tablet or capsule.

12. (Previously presented) The composition of claim 9 wherein the composition is formulated as a Gelcap or suspension.


13. (Previously presented) The composition of claim 10 wherein the cation is sodium.

14. (Currently amended) A contraceptive transdermal patch or implant for administration to the male, wherein said patch or implant comprises a composition comprising a compound of the general formula:




wherein X is P or S;

R is C<sub>4</sub>-C<sub>24</sub> alkyl, C<sub>4</sub>-C<sub>24</sub> alkenyl, C<sub>4</sub>-C<sub>24</sub> alkoxy,



R<sub>1</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, a pharmaceutically acceptable cation



wherein L is 4 to 24;

R<sub>5</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl or a pharmaceutically acceptable cation,

R<sub>2</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl or C<sub>4</sub>-C<sub>24</sub> alkoxy, n is 0 to 4;

R<sub>3</sub>, is C<sub>4</sub>-C<sub>24</sub> alkyl, m is 3 to 10;


R<sub>4</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or COOR<sub>6</sub>;

R<sub>6</sub> is C<sub>1</sub>-C<sub>13</sub> alkyl; and

Y = O or NH.


~~14.~~ 15. (Currently amended) A method of inhibiting the capacitation of sperm cells,

said method comprising the steps of contacting in a male the sperm cells with a composition comprising a compound of the general formula:




wherein X is P or S;

R is C<sub>4</sub>-C<sub>24</sub> alkyl, C<sub>4</sub>-C<sub>24</sub> alkenyl, C<sub>4</sub>-C<sub>24</sub> alkoxy,



R<sub>1</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, a pharmaceutically acceptable cation or



wherein L is 4 to 24;

R<sub>5</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl or a pharmaceutically acceptable cation,

R<sub>2</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl or C<sub>4</sub>-C<sub>24</sub> alkoxy, n is 0 to 4;

R<sub>3</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl, m is 3 to 10;

R<sub>4</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or COOR<sub>6</sub>;


R<sub>6</sub> is C<sub>1</sub>-C<sub>13</sub> alkyl; and

Y = O or NH and a pharmaceutically acceptable carrier.

~~15.~~ 16. (Currently amended – cancelled) The method of claim 14 wherein the step of contacting the sperm cells with the compound occurs *in vivo* in the male.


~~16.~~ 17. (Currently amended) A method for inhibiting contraception, comprising

administering to a male an effective amount of a pharmaceutically acceptable cationic salt of a compound of the general formula:




wherein X is P or S;

R is C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>4</sub>-C<sub>24</sub> alkenyl, C<sub>4</sub>-C<sub>24</sub> alkoxy,



R<sub>1</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, a pharmaceutically acceptable cation or



wherein L is 4 to 24;

R<sub>5</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl or a pharmaceutically acceptable cation,

R<sub>2</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl or C<sub>4</sub>-C<sub>24</sub> alkoxy, n is 0 to 4;

R<sub>3</sub> is C<sub>4</sub>-C<sub>24</sub> alkyl, m is 3 to 10;

R<sub>4</sub> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or COOR<sub>6</sub>;

R<sub>6</sub> is C<sub>1</sub>-C<sub>13</sub> alkyl;

Y = O or NH.

~~17.~~ 18. (Currently amended) The method of claim ~~16~~ 17 wherein the composition is administered orally in a daily dosage form.

~~18.~~ 19. (Currently amended) The method of claim ~~16~~ 17 wherein the composition. is

administered transdermally or subcutaneously to maintain constant systemic levels. for an extended time period.